The Antiarrhythmic Activity of Novel Pyrrolidin-2-one Derivative S-75 in Adrenaline-Induced Arrhythmia

Arrhythmia is a quivering or irregular heartbeat that can often lead to blood clots, stroke, heart failure, and other heart-related complications. The limited efficacy and safety of antiarrhythmic drugs require the design of new compounds. Previous research indicated that pyrrolidin-2-one derivative...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Klaudia Lustyk, Kinga Sałaciak, Paula Zaręba, Agata Siwek, Jacek Sapa, Karolina Pytka
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
R
Acceso en línea:https://doaj.org/article/919015ed90c64d18ab47d372690bf405
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:919015ed90c64d18ab47d372690bf405
record_format dspace
spelling oai:doaj.org-article:919015ed90c64d18ab47d372690bf4052021-11-25T18:39:02ZThe Antiarrhythmic Activity of Novel Pyrrolidin-2-one Derivative S-75 in Adrenaline-Induced Arrhythmia10.3390/ph141110651424-8247https://doaj.org/article/919015ed90c64d18ab47d372690bf4052021-10-01T00:00:00Zhttps://www.mdpi.com/1424-8247/14/11/1065https://doaj.org/toc/1424-8247Arrhythmia is a quivering or irregular heartbeat that can often lead to blood clots, stroke, heart failure, and other heart-related complications. The limited efficacy and safety of antiarrhythmic drugs require the design of new compounds. Previous research indicated that pyrrolidin-2-one derivatives possess an affinity for α<sub>1</sub>-adrenergic receptors. The blockade of α<sub>1</sub>-adrenoceptor may play a role in restoring normal sinus rhythm; therefore, we aimed to verify the antiarrhythmic activity of novel pyrrolidin-2-one derivative S-75. In this study, we assessed the influence on sodium, calcium, potassium channels, and β<sub>1</sub>-adrenergic receptors to investigate the mechanism of action of S-75. Lack of affinity for β<sub>1</sub>-adrenoceptors and weak effects on ion channels decreased the role of these adrenoceptors and channels in the pharmacological activity of S-75. Next, we evaluated the influence of S-75 on normal ECG in rats and isolated rat hearts, and the tested derivative did not prolong the QT<sub>c</sub> interval, which may confirm the lack of the proarrhythmic potential. We tested antiarrhythmic activity in adrenaline-, aconitine- and calcium chloride-induced arrhythmia models in rats. The studied compound showed prophylactic antiarrhythmic activity in the adrenaline-induced arrhythmia, but no significant activity in the model of aconitine- or calcium chloride-induced arrhythmia. In addition, S-75 was not active in the model of post-reperfusion arrhythmias of the isolated rat hearts. Conversely, the compound showed therapeutic antiarrhythmic properties in adrenaline-induced arrhythmia, reducing post-arrhythmogen heart rhythm disorders, and decreasing animal mortality. Thus, we suggest that the blockade of α<sub>1</sub>-adrenoceptor might be beneficial in restoring normal heart rhythm in adrenaline-induced arrhythmia.Klaudia LustykKinga SałaciakPaula ZarębaAgata SiwekJacek SapaKarolina PytkaMDPI AGarticlearrhythmiaantiarrhythmic effectadrenaline-induced arrhythmiaα<sub>1</sub>-adrenoceptorα<sub>1</sub>-adrenolyticspyrrolidin-2-oneMedicineRPharmacy and materia medicaRS1-441ENPharmaceuticals, Vol 14, Iss 1065, p 1065 (2021)
institution DOAJ
collection DOAJ
language EN
topic arrhythmia
antiarrhythmic effect
adrenaline-induced arrhythmia
α<sub>1</sub>-adrenoceptor
α<sub>1</sub>-adrenolytics
pyrrolidin-2-one
Medicine
R
Pharmacy and materia medica
RS1-441
spellingShingle arrhythmia
antiarrhythmic effect
adrenaline-induced arrhythmia
α<sub>1</sub>-adrenoceptor
α<sub>1</sub>-adrenolytics
pyrrolidin-2-one
Medicine
R
Pharmacy and materia medica
RS1-441
Klaudia Lustyk
Kinga Sałaciak
Paula Zaręba
Agata Siwek
Jacek Sapa
Karolina Pytka
The Antiarrhythmic Activity of Novel Pyrrolidin-2-one Derivative S-75 in Adrenaline-Induced Arrhythmia
description Arrhythmia is a quivering or irregular heartbeat that can often lead to blood clots, stroke, heart failure, and other heart-related complications. The limited efficacy and safety of antiarrhythmic drugs require the design of new compounds. Previous research indicated that pyrrolidin-2-one derivatives possess an affinity for α<sub>1</sub>-adrenergic receptors. The blockade of α<sub>1</sub>-adrenoceptor may play a role in restoring normal sinus rhythm; therefore, we aimed to verify the antiarrhythmic activity of novel pyrrolidin-2-one derivative S-75. In this study, we assessed the influence on sodium, calcium, potassium channels, and β<sub>1</sub>-adrenergic receptors to investigate the mechanism of action of S-75. Lack of affinity for β<sub>1</sub>-adrenoceptors and weak effects on ion channels decreased the role of these adrenoceptors and channels in the pharmacological activity of S-75. Next, we evaluated the influence of S-75 on normal ECG in rats and isolated rat hearts, and the tested derivative did not prolong the QT<sub>c</sub> interval, which may confirm the lack of the proarrhythmic potential. We tested antiarrhythmic activity in adrenaline-, aconitine- and calcium chloride-induced arrhythmia models in rats. The studied compound showed prophylactic antiarrhythmic activity in the adrenaline-induced arrhythmia, but no significant activity in the model of aconitine- or calcium chloride-induced arrhythmia. In addition, S-75 was not active in the model of post-reperfusion arrhythmias of the isolated rat hearts. Conversely, the compound showed therapeutic antiarrhythmic properties in adrenaline-induced arrhythmia, reducing post-arrhythmogen heart rhythm disorders, and decreasing animal mortality. Thus, we suggest that the blockade of α<sub>1</sub>-adrenoceptor might be beneficial in restoring normal heart rhythm in adrenaline-induced arrhythmia.
format article
author Klaudia Lustyk
Kinga Sałaciak
Paula Zaręba
Agata Siwek
Jacek Sapa
Karolina Pytka
author_facet Klaudia Lustyk
Kinga Sałaciak
Paula Zaręba
Agata Siwek
Jacek Sapa
Karolina Pytka
author_sort Klaudia Lustyk
title The Antiarrhythmic Activity of Novel Pyrrolidin-2-one Derivative S-75 in Adrenaline-Induced Arrhythmia
title_short The Antiarrhythmic Activity of Novel Pyrrolidin-2-one Derivative S-75 in Adrenaline-Induced Arrhythmia
title_full The Antiarrhythmic Activity of Novel Pyrrolidin-2-one Derivative S-75 in Adrenaline-Induced Arrhythmia
title_fullStr The Antiarrhythmic Activity of Novel Pyrrolidin-2-one Derivative S-75 in Adrenaline-Induced Arrhythmia
title_full_unstemmed The Antiarrhythmic Activity of Novel Pyrrolidin-2-one Derivative S-75 in Adrenaline-Induced Arrhythmia
title_sort antiarrhythmic activity of novel pyrrolidin-2-one derivative s-75 in adrenaline-induced arrhythmia
publisher MDPI AG
publishDate 2021
url https://doaj.org/article/919015ed90c64d18ab47d372690bf405
work_keys_str_mv AT klaudialustyk theantiarrhythmicactivityofnovelpyrrolidin2onederivatives75inadrenalineinducedarrhythmia
AT kingasałaciak theantiarrhythmicactivityofnovelpyrrolidin2onederivatives75inadrenalineinducedarrhythmia
AT paulazareba theantiarrhythmicactivityofnovelpyrrolidin2onederivatives75inadrenalineinducedarrhythmia
AT agatasiwek theantiarrhythmicactivityofnovelpyrrolidin2onederivatives75inadrenalineinducedarrhythmia
AT jaceksapa theantiarrhythmicactivityofnovelpyrrolidin2onederivatives75inadrenalineinducedarrhythmia
AT karolinapytka theantiarrhythmicactivityofnovelpyrrolidin2onederivatives75inadrenalineinducedarrhythmia
AT klaudialustyk antiarrhythmicactivityofnovelpyrrolidin2onederivatives75inadrenalineinducedarrhythmia
AT kingasałaciak antiarrhythmicactivityofnovelpyrrolidin2onederivatives75inadrenalineinducedarrhythmia
AT paulazareba antiarrhythmicactivityofnovelpyrrolidin2onederivatives75inadrenalineinducedarrhythmia
AT agatasiwek antiarrhythmicactivityofnovelpyrrolidin2onederivatives75inadrenalineinducedarrhythmia
AT jaceksapa antiarrhythmicactivityofnovelpyrrolidin2onederivatives75inadrenalineinducedarrhythmia
AT karolinapytka antiarrhythmicactivityofnovelpyrrolidin2onederivatives75inadrenalineinducedarrhythmia
_version_ 1718410848736641024